REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Back to transformations
BeforeBefore
AfterAfter
by Lennox Andersen 478 · 18 days ago

MOTS-c metabolic optimization over 12 weeks. Blood markers improved significantly. Energy levels through the roof.

MOTS-c
2025-09-13 → 2026-03-1826 weeks

Comments (2)

Ellis Kim 129·4 days ago

This gives me hope for my own journey. Thanks for sharing your experience so openly with the community.

Ellis Nakamura 829·3 days ago

Impressive results. The combination you used is interesting - I had not considered that particular stack.

Sign in to comment.